Ukinuta odobrenja, povlačenje serija lijekova, pisma zdravstvenim radnicima i novi lijekovi EU — svakodnevno, automatski. Zadnje ažuriranje: 21. 11. 2026. 08:55
Izvori: promjene pratimo na temelju informacija Agencije za lijekove i medicinske proizvode (HALMED) — rješenja o ukidanju odobrenja, obavijesti o povlačenju serija i pisma zdravstvenim radnicima. Odluke o centralizirano odobrenim lijekovima dolaze iz registra Unije Europske komisije (oznaka EU). Nestašice i liste lijekova HZZO-a ovdje (još) nisu uključene.
br. EU/1/23/1764 · odobreno 1. 12. 2023. · Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG… · UCB Pharma S.A. · zilucoplan · ATC L04AJ06
br. EU/1/18/1318 · odobreno 20. 9. 2018. · Slenyto is indicated for:
- treatment of insomnia in children and adolescents aged 2-18 years with Autism Spe… · RAD Neurim Pharmaceuticals EEC SARL · melatonin · ATC N05CH01
br. EU/1/25/1958 · odobreno 17. 7. 2025. · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · Sandoz GmbH · denosumab · ATC M05BX04
br. EU/1/20/1501 · odobreno 31. 3. 2021. · Paediatric patients
Sogroya is indicated for treatment of growth failure in children and adolescents in the… · Novo Nordisk A/S · somapacitan · ATC H01AC07
br. EU/1/20/1480 · odobreno 24. 9. 2020. · Rheumatoid arthritis:
Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthrit… · Alfasigma S.p.A. · filgotinib · ATC L04AF04
br. EU/1/24/1905 · odobreno 14. 2. 2025. · Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal… · Celltrion Healthcare Hungary Kft. · Denosumab · ATC M05BX04
br. EU/1/20/1439 · odobreno 30. 5. 2020. · Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of ag… · Novartis Europharm Limited · indacaterol / mometasone furoate · ATC R03AK14
Nositelj odobrenja Baxter Holding B.V. je u suradnji s Agencijom za lijekove i medicinske proizvode (HALMED) i Europskom agencijom za lijekove (EMA) uputio pismo zdravstvenim radnicima o dodatnim mjer…
br. EU/1/00/156 · odobreno 28. 12. 2000. · Trizivir is indicated for the treatment of Human Immunodeficiency Virus (HIV) infection in adults (see section… · ViiV Healthcare BV · abacavir, lamivudine, zidovudine · ATC J05AR02
br. EU/1/18/1334 · odobreno 20. 11. 2018. · Vaborem is indicated for the treatment of the following infections in adults:
- Complicated urinary tract inf… · Menarini International Operations Luxembourg S.A. · meropenem/vaborbactam · ATC J01DH52
br. EU/1/95/002 · odobreno 27. 11. 1995. · Breast cancer
TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant t… · Boryung Europe Kft. · Docetaxel · ATC L01CD02
br. EU/1/19/1392 · odobreno 11. 11. 2019. · Ervebo is indicated for active immunisation of individuals 1 year of age or older to protect against Ebola Vir… · Merck Sharp & Dohme B.V. · Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live) · ATC J07BX02
br. EU/1/22/1695 · odobreno 20. 12. 2022. · Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse l… · Swedish Orphan Biovitrum AB (publ) · loncastuximab tesirine · ATC L01FX22
br. EU/1/24/1801 · odobreno 19. 4. 2024. · Plaque psoriasis
Pyzchiva is indicated for the treatment of moderate to severe plaque psoriasis in adults who… · Samsung Bioepis NL B.V. · ustekinumab · ATC L04AC05
br. EU/1/18/1282 · odobreno 16. 5. 2018. · Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who a… · ViiV Healthcare B.V. · dolutegravir / rilpivirine · ATC J05AR21
br. EU/1/11/708 · odobreno 18. 8. 2011. · Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa f… · Orion Corporation · entacapone · ATC N04BX02
br. EU/1/18/1352 · odobreno 15. 2. 2019. · Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic sple… · AOP Orphan Pharmaceuticals GmbH · ropeginterferon alfa-2b · ATC L03AB15